Bayer Aktiengesellschaft (BAYZF)
| Market Cap | 31.90B |
| Revenue (ttm) | 50.34B |
| Net Income (ttm) | -3.52B |
| Shares Out | n/a |
| EPS (ttm) | -3.59 |
| PE Ratio | n/a |
| Forward PE | 6.21 |
| Dividend | 0.13 (0.40%) |
| Ex-Dividend Date | Apr 28, 2025 |
| Volume | n/a |
| Average Volume | 11,446 |
| Open | 31.00 |
| Previous Close | 31.00 |
| Day's Range | 31.00 - 31.00 |
| 52-Week Range | 19.50 - 34.68 |
| Beta | 0.99 |
| RSI | 42.98 |
| Earnings Date | Aug 6, 2025 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skin... [Read more]
Financial Performance
In 2024, Bayer Aktiengesellschaft's revenue was 46.61 billion, a decrease of -2.16% compared to the previous year's 47.64 billion. Losses were -2.55 billion, -13.23% less than in 2023.
Financial numbers in EUR Financial StatementsNews
Bayer gains after raising 2025 outlook
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Bayer Ups Guidance After Pharmaceuticals Unit Outperforms
Bayer increases Roundup litigation provisions by $1.37 billion
German pharmaceutical company Bayer said on Thursday it had set aside an additional 1.2 billion euros ($1.37 billion) in provisions to address ongoing Roundup litigation in the United States.
French court finds complaint brought by family in Bayer glyphosate case inadmissible, media says
A French court ruled on Thursday that a complaint brought by a family against Bayer claiming their son's disabilities were the result of his mother's exposure to glyphosate when pregnant was inadmissi...
Bayer's Elinzanetant review period gets extended by FDA
US FDA extends review of Bayer's menopause relief drug
The U.S. Food and Drug Administration has extended its review of Bayer's experimental menopause relief drug, the German drugmaker said on Friday.
Bayer Provides Regulatory Update on Elinzanetant for the Treatment of Moderate to Severe Hot Flashes Due to Menopause
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Provides Regulatory Update on Elinzanetant for the Treatment of Moderate to Severe Hot Flashes Due to Menopause.
Cory Booker pitches bill to allow lawsuits against pesticide makers over ‘toxic products’
Pesticide Injury Accountability Act would ensure that Bayer, Syngenta and others can be held responsible for allegedly causing health issues US politics live – latest updates Cory Booker on Thursday i...
Bayer AG extends contract of CEO Bill Anderson
Bayer extends contract of CEO until March 2029
Germany's Bayer said on Wednesday that its supervisory board had extended the contract of CEO Bill Anderson until March 31, 2029.
Bayer: Upside Compelling - Buy
Environmentalists object to Punjab govt’s NoC for genetically modified (GM) maize trials; coalition demands inquiry
Environmentalists and GM Free India are protesting Punjab's NoC for GM maize trials, issued over a year after a similar clearance for GM mustard. They've urged the agriculture minister to investigate ...
Bayer gets UK nod for menopausal hot flash therapy
Health Rounds: Experimental Bayer drug eases menopause-like symptoms from breast cancer therapy
The hot flashes and night sweats that plague breast cancer survivors during years-long hormone-suppressing therapy are eased by an experimental non-hormonal drug being developed by Bayer , according t...
Bayer Appoints Priyal Patel as Chief Financial Officer for North America
ST. LOUIS--(BUSINESS WIRE)--Bayer today announced the appointment of Priyal Patel as Cluster Chief Financial Officer (CFO) for North America, effective July 1, 2025. In her new role, Patel will overse...
U.S. Supreme Court seeks federal input on Bayer's Roundup case
US Supreme Court seeks Justice Department views on Bayer's Roundup appeal
The U.S. Supreme Court asked President Donald Trump's administration on Monday for its views on Bayer's bid to sharply limit lawsuits claiming that the company's Roundup weedkiller causes cancer and p...
Bayer says U.S. Supreme Court asks solicitor general for opinion in glyphosate case
Bayer said on Monday that the U.S. Supreme Court had asked the solicitor general for an opinion in the Durnell case, as the German company seeks clarity from the top U.S. court in litigation related t...
Court Approves $38M Cash Settlement Against Bayer AG in Hard-Fought Securities Class Action
Following the Bayer-Monsanto merger, litigation has resulted in a valuable settlement that, pending final approval, affirms the rights of ADR investors to
Bayer, Regeneron get EU nod for Eylea's label extension
Bayer's Eylea 8 mg gets EU approval for extended 6-month dosing for macular degeneration & diabetic macular edema. Read more here.
Bayer share price is rising: does it have more upside?
Bayer share price has bounced back this year, making it one of the best-performing companies in the German DAX Index. It has jumped to €26, up by 45% from its lowest point this year.
EY US & Bayer Win “Artificial Intelligence for Good” Award in 2025 AI Breakthrough Awards Program
Prestigious International Annual Awards Program Honors Standout AI Companies & Solutions Prestigious International Annual Awards Program Honors Standout AI Companies & Solutions
Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars
On Sunday, Exelixis, Inc. (NASDAQ: EXEL) revealed topline results from the STELLAR-303 phase 3 pivotal trial of zanzalintinib (100 mg) combined with atezolizumab . The study includes patients with pr...